What's breaking now, across thousands of outlets.
The heart drug whose failure knocked 9% off Novo’s share price in July had almost no effect at all in its pivotal trial. And data on a cardiovascular candidate from Novartis ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.
Doctors expected an experimental drug that lowers a common risk factor for heart attacks would save patients' lives. The medicine made no difference.
Like cholesterol, inflammation causally contributes to the risk of cardiovascular disease, but findings from the clinical trial ZEUS indicate that the road to targeting inflammation may be less…
Key PointsiShares Global Healthcare ETF features a lower expense ratio and a higher dividend yield than Invesco Pharmaceuticals ETF.
Researchers have identified a unique brain connectivity pattern linked to cocaine use disorder. This biological marker can distinguish patients from healthy individuals and predict whether they will…
The Ghana Health Service (GHS) has announced a mandatory health declaration requirement for all travellers arriving in the country, as Ghana steps up public health surveillance amid growing concerns…
